HTEC - ETF AI Analysis

Top Page

ROBO Global Healthcare Technology and Innovation ETF (HTEC)

Rating:67Neutral

Price Target:―

HTEC’s rating suggests it is a solid but not flawless healthcare technology ETF, balancing some strong, stable leaders with more speculative names. High-quality holdings like Penumbra, Thermo Fisher, and Illumina support the fund through strong financial performance and growth prospects, while weaker positions such as Twist Bioscience and several companies with profitability and valuation challenges weigh on the overall rating. The main risk factor is exposure to multiple firms with financial instability or overvaluation concerns, which can add volatility even within a diversified healthcare tech theme.

Positive Factors

Broad Healthcare Innovation Focus

The fund targets a wide range of healthcare technology and innovation companies, giving investors exposure to a fast-evolving part of the health sector.

Many Strong-Performing Top Holdings

Most of the largest positions, including names like Moderna and several biotech and diagnostics firms, have shown strong gains this year, helping support the ETF’s recent performance.

Improving Recent Performance

The ETF has delivered solid gains over the past three months and year-to-date, suggesting positive momentum in its underlying holdings.

Negative Factors

High Sector Concentration

With almost all assets in healthcare and only a small slice in technology, the fund is heavily exposed to swings in a single sector.

Limited Geographic Diversification

The portfolio is dominated by U.S. companies, which reduces the benefits of international diversification and ties results closely to the U.S. market.

Relatively High Expense Ratio

The fund’s management fee is on the higher side for an ETF, which can gradually reduce net returns for long-term investors.

HTEC vs. SPDR S&P 500 ETF (SPY)

AUM53.26M

RegionGlobal

Expense Ratio0.68%

Beta0.93

IssuerROBO Global

Inception DateJun 25, 2019

Dividend Yield0.98%

Asset ClassEquity

Index TrackedROBO Global Healthcare Technology and Innovation ETF

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume9,324

30 Day Avg. Volume7,598

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

43.29

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering62

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

HTEC Summary

HTEC is an ETF that follows the ROBO Global Healthcare Technology and Innovation index, focusing on companies using technology to improve healthcare. It holds firms involved in areas like medical robotics, telehealth, genetic testing, and AI in medicine. Well-known holdings include Moderna and Thermo Fisher. Someone might invest in HTEC to seek long-term growth from the rising use of advanced healthcare tools and to get a diversified basket of innovative health-tech companies in one fund. A key risk is that it is heavily focused on healthcare technology, so its price can swing more than the overall market.

How much will it cost me?The ROBO Global Healthcare Technology and Innovation ETF (HTEC) has an expense ratio of 0.68%, which means you’ll pay $6.80 per year for every $1,000 invested. This is higher than average because it is actively managed and focuses on a specialized niche in healthcare technology, requiring more research and expertise. It offers exposure to innovative companies in areas like medical robotics and genomic sequencing.

What would affect this ETF?HTEC could benefit from growing demand for healthcare innovation, driven by advancements in medical robotics, telehealth, and AI applications, as well as increased global focus on improving healthcare efficiency and outcomes. However, the ETF may face challenges from regulatory changes in healthcare technology, potential economic slowdowns impacting funding for innovation, or competition within the sector. Its global exposure and focus on cutting-edge companies position it well for long-term growth, but risks remain tied to sector-specific volatility.

HTEC Top 10 Holdings

HTEC is a pure play on healthcare innovation, with nearly all its firepower in global medtech and biotech rather than broad tech or other sectors. Recent strength from names like Moderna, Guardant Health, Penumbra, and Illumina has been pushing the fund forward, as investors warm back up to genomic and diagnostic stories. Twist Bioscience and Adaptive Biotechnologies are more of a mixed bag, with exciting growth but nagging profitability issues, while Siemens Healthineers has been treading water, acting more like ballast than a real engine for returns.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
TWST	Twist Bioscience	2.35%	$1.25M	$2.91B	2.75%	43 Neutral
MRNA	Moderna	2.16%	$1.15M	$16.39B	37.38%	59 Neutral
PEN	Penumbra	2.07%	$1.10M	$13.30B	26.37%	78 Outperform
VRTX	Vertex Pharmaceuticals	2.07%	$1.10M	$119.47B	3.90%	78 Outperform
GH	Guardant Health	2.06%	$1.10M	$13.63B	141.60%	61 Neutral
ARWR	Arrowhead Pharmaceuticals	2.04%	$1.08M	$8.77B	237.32%	57 Neutral
AXGN	AxoGen	2.03%	$1.08M	$1.70B	93.66%	69 Neutral
NOVT	Novanta	2.01%	$1.07M	$5.16B	-1.62%	70 Neutral
REGN	Regeneron	2.00%	$1.06M	$82.48B	17.54%	78 Outperform
ERF	Eurofins Scientific	1.98%	$1.06M	€12.24B	33.48%	64 Neutral

HTEC Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price―

Price Trends

50DMA

36.24

Negative

100DMA

34.20

Positive

200DMA

31.20

Positive

Market Momentum

MACD

-0.19

Positive

RSI

39.45

Neutral

STOCH

12.25

Positive

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HTEC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 36.87, equal to the 50-day MA of 36.24, and equal to the 200-day MA of 31.20, indicating a neutral trend. The MACD of -0.19 indicates Positive momentum. The RSI at 39.45 is Neutral, neither overbought nor oversold. The STOCH value of 12.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HTEC.

HTEC Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
HTEC	―	―	$53.26M	0.68%	―
FMED	―	―	$60.03M	0.50%	―
OZEM	―	―	$58.08M	0.59%	―
HRTS	―	―	$56.59M	0.75%	―
GDOC	―	―	$20.60M	0.75%	―
LGHT	―	―	$3.85M	0.85%	―

Performance Comparison

HTEC

ROBO Global Healthcare Technology and Innovation ETF

35.44

5.86

19.81%

FMED

Fidelity Disruptive Medicine ETF

―

OZEM

Roundhill GLP-1 & Weight Loss ETF

―

HRTS

Tema Cardiovascular and Metabolic ETF

―

GDOC

Goldman Sachs Future Health Care Equity ETF

―

LGHT

Langar Global HealthTech ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents